Lilly Receives FDA Approval for Emgality (galcanezumab-gnlm) for Preventive Treatment of Migraine in Adults
Shots:
- Emgality’s approval is based on two P-III trials (N=425) (EVOLVE-1 and EVOLVE-2) and one P-III REGAIN trial (N=450) administering once monthly PBO vs Emgality 120 mg after an initial dose of 240 mg- or Emgality 240 mg- evaluating its safety and efficacy
- P-III EVOLVE-1 & EVOLVE-2 Results: mean change from baseline days (4.7 vs -2.8) & (4.3 vs-2.3)- @50% reduction in migraine headache days (MHDs) (62% vs 39%)& (59% vs 36%)- @75% in MHD (39% vs 19%) & (34% vs 18%)- @100% MHD (16% vs 6%) & (12% vs 6%); REGAIN Results: mean change from baseline days (4.8 vs -2.7)- @50% MHD (28% vs 15%)
- Emgality IV self-administered recommended dose is 240 mg (two consecutive SC IV of 120 mg each) once as a loading dose- followed by monthly doses of 120 mg. The US list price of Emgality is $575 once monthly- or $6-900 annually
Ref: Lilly | Image: Market Exclusive
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com